A comprehensive study examining cannabis psychosis risk in Canada has revealed alarming increases in cannabis use disorder (CUD) diagnoses associated with schizophrenia and psychosis following the country’s cannabis legalisation policies.

The research, published in JAMA Network Open, investigated the population-attributable fraction (PARF) for cannabis use disorder linked to serious mental health conditions across three distinct cannabis policy periods in Ontario, Canada.

Significant Increases Across Policy Periods

Researchers leveraged retrospective population-based data of Ontario residents aged 18-64 between 2006 and 2022, tracking changes through three critical periods: pre-legalisation (2006-2015), liberalisation of medical cannabis and non-medical cannabis (2015-2018), and legalisation of non-medical cannabis (2018-2022).

The findings reveal that cannabis psychosis risk in Canada escalated dramatically. The PARF for CUD associated with schizophrenia significantly increased from 4% in the pre-legalisation period to 10% post-legalisation—a 150% increase that underscores growing marijuana mental health dangers.

Even more concerning, the PARF for CUD associated with psychosis not otherwise specified (NOS) surged from 5% before legalisation to 12% afterwards, representing a substantial 140% rise in cannabis psychosis risk in Canada.

Young Men Face Highest Risk

The study identified men aged 19-24 as experiencing the highest PARF post-legalisation, highlighting this demographic’s particular vulnerability to marijuana mental health dangers following policy changes.

Moreover, whilst gradual increases in PARF for CUD associated with schizophrenia occurred across all policy periods, researchers noted an acceleration in PARF for CUD associated with psychosis NOS specifically after medical cannabis liberalisation.

Complex Factors Behind Rising Risks

The research reveals that cannabis psychosis risk in Canada appears influenced by multiple factors beyond legal status alone. The steady increase of CUD associated with schizophrenia across all policy reform periods suggests other contributing elements may be at play.

These factors include a drop in perceived risk among the population, increased potency of cannabis products available on the market, and enhanced accessibility of products following legalisation. Furthermore, the combination of these elements appears to be amplifying marijuana mental health dangers across Canadian society.

Policy Implications and Research Directions

Dr Emily Nields, commenting on the study, emphasised that whilst CUD associated with psychosis NOS accelerated with liberalisation of cannabis in this population, the steady increase of CUD associated with schizophrenia across policy reform periods suggests that other factors could be at play.

Additionally, she noted that rates of new CUD diagnoses associated with shifts in cannabis policy could be the subject of future studies to inform policymakers as they weigh decisions related to cannabis reform.

The findings highlight the complex relationship between cannabis policy changes and mental health outcomes, particularly concerning cannabis psychosis risk in Canada among vulnerable populations.

Understanding the Three-Period Analysis

The comprehensive nature of this research lies in its examination of cannabis psychosis risk in Canada across distinct policy phases. This approach allowed researchers to identify not only overall trends but also specific acceleration points in marijuana mental health dangers.

The pre-legalisation period (2006-2015) established baseline measurements, whilst the liberalisation phase (2015-2018) showed initial increases, and the full legalisation period (2018-2022) revealed the most dramatic escalations in risk factors.

Broader Context for Cannabis Policy

The study’s methodology, examining population-attributable fractions across multiple policy periods, provides crucial evidence about cannabis psychosis risk in Canada that extends beyond simple correlation. Nevertheless, the research demonstrates clear associations between policy changes and increased prevalence of serious mental health conditions.

These findings serve as important considerations for jurisdictions worldwide contemplating similar cannabis policy reforms, particularly regarding the need to address marijuana mental health dangers through comprehensive public health strategies.

The evidence suggests that cannabis psychosis risk in Canada has become a significant public health concern requiring targeted interventions, especially for young adult populations who appear most susceptible to policy-related changes in cannabis accessibility and social acceptance.